Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05525741
Other study ID # 22-PP-10
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date October 19, 2022
Est. completion date August 30, 2024

Study information

Verified date March 2024
Source Centre Hospitalier Universitaire de Nice
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To compare the level of circulating functional mitochondria in the serum of vitiligo patients as compared to controls


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 59
Est. completion date August 30, 2024
Est. primary completion date April 1, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - Patients with non segmental vitiligo, - atopic dermatitis, psoriais, alopecia areata, - 1st degree relative of vitiligo patients. Exclusion Criteria: - segmental or mixed vitiligo, - personnal history of other autoimmune disorders, - oral use of antioxidant, - pregant women

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Non segmental vitiligo
The subjects will be selected from among those presenting for the consultation or hospitalization of the Dermatology department of the CHU de Nice. All necessary information will be given to the subjects and a briefing note will be given to them. A reflection period will be left for the subjects to sign the informed consent, and if necessary, another appointment will be scheduled for the inclusion visit. The Investigator: Inform the subject of the goals, constraints and risks of the study and obtain written consent. Conduct an examination of the subject's medical history Will verify that the subject meets all inclusion criteria and does not present any of the criteria for not including. If the subject consents and they meet all the criteria a 20 ml blood sample will be taken.
Health Volunteers
The subjects will be selected from among those presenting for the consultation or hospitalization of the Dermatology department of the CHU de Nice. The family control subjects will be recruited from the vitiligos patients coming into our department. All necessary information will be given to the subjects and a briefing note will be given to them. A reflection period will be left for the subjects to sign the informed consent, and if necessary, another appointment will be scheduled for the inclusion visit. The Investigator: Inform the subject of the goals, constraints and risks of the study and obtain written consent. Conduct an examination of the subject's medical history Will verify that the subject meets all inclusion criteria and does not present any of the criteria for not including. If the subject consents and they meet all the criteria a 20 ml blood sample will be taken.

Locations

Country Name City State
France CHU de Nice - Hôpital de l'Archet Nice Alpes-maritimes

Sponsors (1)

Lead Sponsor Collaborator
Centre Hospitalier Universitaire de Nice

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Total number of circulating functionnal mitochondria (CFM) in the plasma Level of CFM in vitiligo serum as compared to controls at baseline
Secondary measuring the functionality of circulating mitochondria Functional analysis of CFM in vitiligo patients as compared to controls analyzed by MFI Mito Tracker At baseline
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04971200 - Pilot Study Assessing the Effect of Tildrakizumab in Vitiligo Early Phase 1
Completed NCT02379793 - Skin Irritation Test of LEO 80185 Gel in Healthy Japanese Subjects Phase 1
Completed NCT01093911 - Safety Study of CDP7657 in Healthy Volunteers and Patients With Systemic Lupus Erythematosus (SLE) Phase 1
Completed NCT00147511 - Time To Efficacy and Onset Of Action Of Linezolid Phase 4
Completed NCT02355639 - A Single-Centre Clinical Trial to Assess Steroid Induced Skin Atrophy on Healthy Skin Phase 1
Completed NCT01764594 - Safety Study of CDP7657 in Patients With Systemic Lupus Erythematosus Phase 1
Active, not recruiting NCT05185258 - Residual Disease MEMory in PSOriasis Skin During EnstiLAR® and Narrow-band Ultraviolet B Therapy: The MEMPSOLAR Study Phase 4
Completed NCT02985437 - Safety and Tolerability of Topically Applied Bovine Lung Surfactant on Intact Skin Phase 1
Not yet recruiting NCT06427889 - Treatment Effects of Two Pharmaceutical Skin Care Creams for Xerotic Feet Among Persons With Diabetes Phase 4
Completed NCT02518048 - A Psoriasis Plaque Test Trial With LEO 90100 Compared to Betesil® in Patients With Psoriasis Vulgaris Phase 2
Withdrawn NCT03196115 - Biomarker for Hyaline Fibromatosis Syndrome (BioHFS)
Completed NCT02416258 - A Psoriasis Plaque Test Trial With LP0113 Spray in Patients With Psoriasis Vulgaris (LP0113-1123) Phase 2